A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies

Active:	Yes
Cancer Type:	Hodgkin Lymphoma Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes (MDS) Non-Hodgkin Lymphoma Skin Cancer (Non-Melanoma) Unknown Primary	NCT ID:	NCT03218683
Trial Phases:	Phase I	Protocol IDs:	D6910C00001 (primary) NCI-2017-01390
Eligibility:	18 to 85, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT03218683

Summary

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation

study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of

ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.